You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
1 May 2014
Merrimack Pharmaceuticals Announces MM-398 Achieves Primary Endpoint of Overall Survival in Phase 3 Trial in Post-Gemcitabine Metastatic Pancreatic Cancer